0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover904.34%IV126.59%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.3595Delta0.1167Gamma6.62Leverage Ratio-0.1474Theta0.0001Rho2.38Eff Leverage0.0013Vega
Mural Oncology Stock Discussion
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
👃
👄
$Mural Oncology(MURA.US)$
No comment yet